08048035996
Enhertu 100 mg Good Quality Injection to UK - Birmingham | Phoenix Exim | Trusted Exporter

1. General Information

Enhertu 100 mg Injection is an oncology medicine containing trastuzumab deruxtecan. It is designed to target cancer cells that express the HER2 protein or, in certain lung cancers, have an activating HER2 mutation.

Enhertu is a prescription-only medicine and should be used only under the supervision of an experienced oncology specialist.

2. Product Information

  • Brand: Enhertu
  • Strength: 100 mg
  • Active ingredient: Trastuzumab deruxtecan
  • Dosage form: Lyophilized powder for concentrate for solution for infusion
  • Route: Intravenous infusion
  • Therapeutic class: Antineoplastic / targeted cancer therapy
  • Drug type: Antibody-drug conjugate (ADC)
  • Manufacturer/marketing authorization holder: Daiichi Sankyo
  • Storage: Store according to the manufacturer's approved product labeling and handling requirements.

The exact dose depends on the cancer type, treatment regimen, body weight, previous therapies, and the patient's clinical condition.

3. Uses of Enhertu 100 mg Injection

Depending on the applicable regulatory approval, Enhertu is used for certain:

  • HER2-positive breast cancers
  • HER2-low and HER2-ultralow metastatic breast cancers
  • HER2-mutant non-small cell lung cancer (NSCLC)
  • HER2-positive gastric or gastroesophageal junction (GEJ) cancer
  • Certain HER2-positive unresectable or metastatic solid tumors

Patient selection depends on the cancer type and appropriate biomarker testing. Current indications differ somewhat between countries, so the local approved prescribing information should always be followed.

4. Benefits of Enhertu

Enhertu provides a targeted treatment approach by combining a HER2-targeting antibody with a chemotherapy payload.

Potential clinical benefits include:

  • Specifically targets HER2-expressing cancer cells.
  • Delivers the cytotoxic component directly into targeted cancer cells.
  • Can inhibit cancer-cell growth through HER2 signaling blockade.
  • Has demonstrated tumor responses in several approved cancer settings.
  • Provides an established treatment option for appropriately selected patients with certain HER2-positive, HER2-low, HER2-ultralow, or HER2-mutated cancers.

5. Side Effects of Enhertu

Enhertu can cause side effects, and some can be serious. Important adverse reactions include:

  • Interstitial lung disease (ILD) or pneumonitis
  • Neutropenia
  • Anemia
  • Thrombocytopenia
  • Nausea and vomiting
  • Fatigue
  • Decreased appetite
  • Diarrhea or constipation
  • Hair loss
  • Abnormal liver-function tests
  • Musculoskeletal pain
  • Left ventricular dysfunction
  • Infusion-related reactions

ILD/pneumonitis can be severe, life-threatening, or fatal, making respiratory symptoms particularly important to report promptly.

6. Common Side Effects

Commonly reported adverse reactions include:

  • Nausea
  • Fatigue
  • Vomiting
  • Reduced appetite
  • Constipation
  • Diarrhea
  • Hair loss
  • Anemia
  • Low white blood cell/neutrophil counts
  • Low platelet counts
  • Increased liver enzymes
  • Muscle and bone pain

The frequency and severity can vary according to the cancer being treated and the treatment regimen.

7. How to Use Enhertu 100 mg Injection

Enhertu is not a self-administered injection. It is prepared and administered as an intravenous infusion by trained healthcare professionals.

The dosing schedule depends on the indication. For example, the EMA describes administration by IV infusion once every three weeks, with the first infusion generally given over 90 minutes and subsequent infusions potentially over 30 minutes if the first is tolerated.

The prescribing oncologist determines:

  • Appropriate dose
  • Infusion schedule
  • Treatment duration
  • Dose interruptions or reductions
  • Whether treatment should be discontinued

8. How Enhertu Works

Enhertu is an antibody-drug conjugate consisting of trastuzumab linked to the chemotherapy payload deruxtecan.

  1. The trastuzumab component binds to HER2 on targeted cancer cells.
  2. The drug is taken into the cancer cell.
  3. Deruxtecan is released inside the cell.
  4. Deruxtecan inhibits topoisomerase I, an enzyme involved in DNA replication.
  5. This causes DNA damage and can lead to cancer-cell death.

The trastuzumab component also interferes with HER2 signaling and can contribute to immune-mediated destruction of cancer cells.

9. Safety Advice

  • Use Enhertu only under specialist oncology supervision.
  • Patients should be monitored for new or worsening cough, shortness of breath, fever, or other respiratory symptoms, because these can indicate ILD/pneumonitis.
  • Blood counts should be monitored because neutropenia and other blood-cell abnormalities can occur.
  • Heart function, including left ventricular ejection fraction, should be assessed as clinically appropriate.
  • Tell the healthcare professional about all medicines and supplements being taken.
  • Enhertu can cause embryo-fetal harm; pregnancy should be avoided during treatment according to the applicable prescribing information.
  • Report infusion-related symptoms such as fever, chills, flushing, or breathing difficulties promptly.
  • Do not confuse or interchange Enhertu with other trastuzumab-containing medicines such as Kadcyla; medication errors can occur because their names and active substances are similar.

10. Frequently Asked Questions

Q1. What is Enhertu 100 mg Injection?
Enhertu 100 mg is an intravenous cancer medicine containing trastuzumab deruxtecan, an antibody-drug conjugate targeting HER2.

Q2. What cancers can Enhertu treat?
It is approved for specific HER2-positive, HER2-low/HER2-ultralow, or HER2-mutated cancers, depending on the country and the patient's biomarker and treatment history.

Q3. How is Enhertu administered?
It is administered as an intravenous infusion by a healthcare professional.

Q4. How often is Enhertu given?
Many approved regimens use an every-three-week schedule, but the exact dose and schedule depend on the indication.

Q5. Can Enhertu cause lung problems?
Yes. ILD and pneumonitis are important risks and can be serious or fatal. New respiratory symptoms should be reported immediately.

Q6. Can Enhertu cause hair loss?
Yes. Alopecia is among the commonly reported adverse reactions.

Q7. Is Enhertu a chemotherapy medicine?
It is more specifically an antibody-drug conjugate: a HER2-targeting antibody delivers a potent chemotherapy payload to targeted cells.

Q8. Can Enhertu be used during pregnancy?
Enhertu can cause embryo-fetal harm and should not be used during pregnancy unless specifically determined appropriate by the treating specialist.

11. Substitute for Enhertu

There is no single universal substitute for Enhertu. The appropriate alternative depends on:

  • Cancer type and stage
  • HER2 status
  • Previous treatments
  • Patient health and organ function
  • Local treatment guidelines
  • Availability and regulatory approval

Other HER2-directed medicines, such as trastuzumab, trastuzumab emtansine (Kadcyla), pertuzumab, or other targeted therapies, may be considered in particular clinical situations, but they are not automatically interchangeable with Enhertu. The treating oncologist should select any alternative.

12. SEO Keywords

Primary keywords:

  • Enhertu 100 mg Injection
  • Enhertu 100 mg
  • Enhertu injection supplier
  • Enhertu injection exporter
  • Enhertu 100 mg exporter from India
  • Trastuzumab deruxtecan 100 mg
  • Trastuzumab deruxtecan injection supplier
  • Trastuzumab deruxtecan exporter India
  • HER2 targeted cancer medicine supplier
  • HER2 targeted therapy exporter

B2B / Export Keywords:

  • Buy Enhertu 100 mg from India
  • Enhertu 100 mg wholesale supplier India
  • Enhertu 100 mg pharmaceutical exporter
  • Enhertu 100 mg medicine exporter Nagpur
  • Enhertu injection wholesale supplier
  • Trastuzumab deruxtecan pharmaceutical exporter
  • Oncology medicine exporter from India
  • Cancer medicine supplier from India
  • Pharmaceutical export company Nagpur
  • Trusted medicine exporter from Nagpur India
  • Enhertu supplier for USA
  • Enhertu supplier for UK
  • Enhertu supplier for Australia
  • Enhertu supplier for Singapore
  • Enhertu supplier for Canada
  • Enhertu supplier for South Korea
  • Enhertu supplier for UAE

Phoenix Exim SEO phrases:

  • Phoenix Exim Enhertu 100 mg exporter
  • Phoenix Exim trastuzumab deruxtecan supplier
  • Phoenix Exim oncology medicine exporter from Nagpur
  • Phoenix Exim cancer medicine exporter India
  • Phoenix Exim pharmaceutical supplier India
  • Enhertu 100 mg export supplier Phoenix Exim
Aug 14th, 2026 3:46 PM

Keywords